
ACET Stock Forecast & Price Target
ACET Analyst Ratings
Bulls say
Adicet Bio Inc is positioned favorably due to its innovative approach in leveraging allogeneic gamma delta T cell therapies, particularly through its lead candidate, ADI-001, which shows significant efficacy in treating autoimmune diseases like lupus nephritis and systemic lupus erythematosus. The upcoming Phase 1 study of ADI-212 in metastatic castration-resistant prostate cancer, with initial data expected by the latter half of 2026, could serve as a critical value inflection point, highlighting the company's expanding oncology focus. Additionally, the decision to contract third-party manufacturers for commercial-scale production is anticipated to mitigate manufacturing risks, thereby supporting future growth and enhancing the overall investment outlook for Adicet Bio.
Bears say
Adicet Bio Inc is projecting a net loss of $1.13 per share for 2025, indicating ongoing financial challenges. The company faces significant risks, including potential negative clinical data, slower-than-expected development timelines, and a heightened regulatory risk due to the absence of FDA approvals for any Vδ1 gamma-delta T-cell therapies. Additionally, a lowered probability of success for ADI-001 in treating certain conditions, alongside competitive pressures that could dilute market share and revenue prospects, contribute to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ACET Analyst Forecast & Price Prediction
Start investing in ACET
Order type
Buy in
Order amount
Est. shares
0 shares